PAI-1 As a Therapeutic Target: A State-of-the-Art Review

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Plasminogen activator inhibitor (PAI-1) is a key regulator of fibrinolysis.
• PAI-1 is implicated in numerous pathologies, including cardiovascular disease, metabolic disorders, cancer, and aging.
• Despite its significance, no specific FDA or EMA-approved PAI-1 therapeutics currently exist.

Purpose of the Study:

• To review current therapeutic strategies targeting PAI-1.
• To identify challenges in PAI-1 inhibitor development.
• To discuss future directions for PAI-1-targeted therapies.

Main Methods:

• Literature review of PAI-1 research and therapeutic development.
• Analysis of small molecules, RNA aptamers, monoclonal antibodies, and repurposed drugs.
• Examination of PAI-1's interaction with mediators like vitronectin.

Main Results:

• Various therapeutic strategies are under investigation, including small molecules, aptamers, antibodies, and repurposed drugs.
• Significant challenges exist, such as PAI-1's interaction with vitronectin and its complex, tissue-specific effects.
• Successful interventions may require precise, tissue- and temporal expression-based approaches.

Conclusions:

• Further research into PAI-1's structural dynamics and disease roles is essential.
• Developing effective PAI-1 therapeutics requires overcoming complex biological interactions.
• Targeting PAI-1 holds promise for broad medical applications, pending further characterization and refined strategies.